Researchers found that one’s immune system can re-engage to destroy tumors after combining chemotherapy and immunotherapy in mice.
Chemotherapy remains the first-line approach for the treatment of solid tumors. It is based on the cytotoxic activity on rapidly dividing cells, but adverse effects are seen on healthy cells that also rapidly divide, such as the intestinal mucosal lining, and hair follicles.
An independent study published by the MD Anderson Cancer Center in Houston TX cites using HemaCare PBMCs to take a closer look at the SARS-CoV-2 virus to identify which of its peptide sequences would make the most effective vaccine targets.
Early in the COVID-19 pandemic, the primary goal for scientists across the globe was to save lives by developing a safe, working vaccine as quickly as possible. To that end, they succeeded admirably; with several vaccines approved, doctors finally have a powerful way to fight back against this deadly disease.
Researchers involved in the clinical investigation of a new COVID-19 vaccine cited using HemaCare healthy donor starting materials for their study.
The scientists, most of whom work at ImmunityBio in Culver City, CA, are conducting a Phase 1 clinical trial for their new dual-antigen COVID-19 vaccine. [1]
A new publication by scientists at the Cell and Gene Therapy Catapult in the UK cites the use of HemaCare-sourced CD3+ T cells for their cancer immunotherapy research.
The successful commercialization of gene-modified cell therapies relies in part on being able to manufacture a consistent product. Many cell and gene therapy developers use lentiviral vector delivery systems to impart the therapeutic gene modifications necessary to making their therapies effective.
An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]
The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.